Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Neoplasms × Thyroxine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Thyroid Neoplasms 1 Postoperative Complications 1 Neoplasms 1 Hypothyroidism 1

Interventions

Cisplatin 9 pembrolizumab 5 Radiosurgery 5 Gemcitabine 5 Taxes 4 Paclitaxel 4 Dexamethasone 4 trametinib 3 ibrutinib 3 Surveys and Questionnaires 3 Standard of Care 3 Radiotherapy 3 Nivolumab 3 Magnetic Resonance Spectroscopy 3 Fluorouracil 3 Carboplatin 3 Ascorbic Acid 3 tocilizumab 2 pazopanib 2 obinutuzumab 2 naquotinib 2 lenvatinib 2 fludarabine 2 enzalutamide 2 Trastuzumab 2 Surgical Procedures, Operative 2 SS1(dsFv)PE38 2 Radiation Dose Hypofractionation 2 Pemetrexed 2 Ondansetron 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02548715 2022-07-13

LSHT

University of Alberta

Phase 2/3 Withdrawn

Hypothyroidism, Neoplasms, Postoperative Complications

Data powered by HemOnc (CC BY 4.0) Colophon ⚡